Receptor activator of nuclear factor kappa-B ligand pathway (RANK/RANKL/OPG pathway)

The receptor activator of nuclear factor kappa-B ligand pathway, also known as the RANK/RANKL/osteoprotegerin axis, is central to regulating skeletal homeostasis through control over osteoclast development, activation, and survival. In this system: - Osteoblasts produce both membrane-bound/secretable forms of RANK ligand (RANLK) which binds its cognate receptor (RAN K) expressed on preosteoclastic cells. This interaction triggers intracellular signaling cascades—primarily via TRAF6—that activate NF-kB/MAPK pathways leading to upregulation of NFATc1, driving differentiation into mature osteoclasts responsible for bone resorption. - Osteoprotegerin acts as a soluble decoy receptor, binding free circulating/membrane-bound RANLK with high affinity so that it cannot interact with its functional receptor on preosteoclastic cells—thus inhibiting excessive osteoclastic activity. Beyond skeletal regulation, this axis also plays roles in immune cell maturation/survival/differentiation, vascular biology, cancer metastasis, inflammation, sarcopenia/muscle wasting, among others. Dysregulation leads not only to osteoporosis but also contributes mechanistically to rheumatoid arthritis progression/inflammatory joint destruction/cardiovascular pathology including arterial calcification. This makes the receptor activator for nuclear factor kappa-B ligand pathway an important therapeutic target across multiple disease areas, especially those involving abnormal tissue remodeling or chronic inflammation.

Other names

RANK/RANKL/OPG axisRANK–RANKL–osteoprotegerin systemTNFSF11 signaling axis (for RANKL)OPG/RANKL/RANK system

Drugs such as denosumab act by: - Binding to RANKL, preventing its interaction with the receptor RANK on osteoclast precursors. - Inhibiting osteoclastogenesis and reducing bone resorption. - Increasing bone mineral density by shifting the balance toward bone formation over resorption. Small molecules may increase OPG levels or decrease expression/activity of either RANK or downstream effectors involved in osteoclast differentiation.